Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

196.52 +1.02 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
48 49 Next >
News headline image
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ↗
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio. 
Via Talk Markets
News headline image
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent ↗
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. 
Via Benzinga
News headline image
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Why Is Biogen (BIIB) Stock Up 40% Today? ↗
Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors. 
Via InvestorPlace
News headline image
14 Analysts Have This to Say About Biogen ↗
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
News headline image
Netflix, Biogen And Other Big Gainers From Wednesday ↗
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
7 Growth Stocks to Buy to Tap Into a Hidden Bull Market ↗
It's become a bit easier for investors to find growth stocks to buy hidden amid the bear market. 
Via InvestorPlace
News headline image
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Biogen 20 Years Ago Would Be Worth Today ↗
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.9% on an annualized basis producing an average annual return of 10.93%. Currently, Biogen has a market capitalization of... 
Via Benzinga
News headline image
Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods ↗
Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to... 
Via Benzinga
News headline image
What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data ↗
Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results ↗
Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring. 
Via InvestorPlace
News headline image
Why Is Prothena (PRTA) Stock Up 75% Today? ↗
Prothena (PRTA) stock is seeing massive gains on Wednesday despite a lack of recent news from the late-stage clinical company. 
Via InvestorPlace
News headline image
Why Is Acumen (ABOS) Stock Up 95% Today? ↗
Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company. 
Via InvestorPlace
News headline image
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗
 
Via Benzinga
News headline image
BMO Capital Upgrades Biogen: Here's What You Need To Know ↗
BMO Capital upgraded its rating of Biogen (NASDAQ:BIIB) to Outperform with a price target of $360.00, changing its price target from $217.00 to $360.00. Shares of Biogen are trading up 37.95% over the... 
Via Benzinga
News headline image
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37% ↗
Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital... 
Via Benzinga
News headline image
Why Acumen Pharmaceuticals Stock Is Soaring Today ↗
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink: 
Via Benzinga
News headline image
Why Is Cassava Sciences (SAVA) Stock Heating Up Today? ↗
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022 ↗
Upgrades 
Via Benzinga
News headline image
These Analysts Boost Price Targets On Biogen Following Positive Alzheimer's Drug Data, Shares Jump ↗
Biogen, Inc. (NASDAQ: BIIB) shares jumped sharply on Wednesday. 
Via Benzinga
News headline image
Biogen Explodes Higher After Alzheimer's Drug Succeeds In Final-Phase Test ↗
The drug not only removed beta amyloid, but led to a cognitive benefit. 
Via Investor's Business Daily
News headline image
Netflix To Rally Around 24%? Here Are 5 Other Price Target Changes For Wednesday ↗
Atlantic Equities raised Netflix, Inc. (NASDAQ: NFLX) price target from $211 to $283. Atlantic Equities analyst Hamilton Faber also upgraded the stock from Neutral to Overweight. Netflix shares rose... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
News headline image
Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28 ↗
Bloomberg 
Via Benzinga
News headline image
What In The World Is Going On With Biogen (BIIB) Shares? ↗
Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co. 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.